Diagonal Therapeutics的动态

SFBN Feed: Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors https://lnkd.in/gUMXm49T BEIJING & ALAMEDA, Calif. & TAIPEI–(BUSINESS WIRE)–Biocytogen (HKEX: 02315) and Acepodia (6976:TT), today announced a groundbreaking strategic partnership to jointly assess a dual-payload bispecific antibody-drug conjugate (BsAD2C) program. This collaboration combines Biocytogen’s RenLite? platform with [...] #BayArea #SanFrancisco #Biotech #Lifescience #News

The design of antibody-drug conjugates has advanced considerably since initial efforts more than four decades ago. Thanks to the variety of payloads, linkers, and conjugation technologies, combined with different antibody targets and formats, more than 180 ADCs are currently in clinical development. In this Drug Target Review article, Zymeworks’ Paul Moore, PhD, Raffaele Colombo, PhD, and Jamie Rich, PhD, discuss how we leverage insights gained from clinical trials and real-world clinical experience to design and develop highly differentiated ADC therapeutics. Read the full article: https://lnkd.in/ecVhiuqp

SFBN Trending News: Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors https://lnkd.in/gn8EHtMm BEIJING & ALAMEDA, Calif. & TAIPEI–(BUSINESS WIRE)–Biocytogen (HKEX: 02315) and Acepodia (6976:TT), today announced a groundbreaking strategic partnership to jointly assess a dual-payload bispecific antibody-drug conjugate (BsAD2C) program. This collaboration combines Biocytogen’s RenLite? platform with [...]

Missed the webinar? No problem! ?? Watch the playback of "Accelerating Antibody Drug Discovery with Fully Human Antibody Mouse HUGO-Ab? and High-Throughput Single B Cell Screening AbDrop?". ?? https://lnkd.in/gBtAEYWS ?? Ready to elevate your antibody drug discovery journey? Share your thoughts and explore further insights in the comments below! #Webinar #AntibodyDrugDiscovery #HUGOAb #AbDrop #Biotech #Research #Cyagen #antibody #scienceandcommunication

Authors describe the discovery, mechanism of action, and preclinical anti-MM activity of engineered toxin body MT-0169, a next-generation immunotoxin comprising a CD38-specific antibody fragment linked to a de-immunized Shiga-like toxin A subunit (SLTA) payload.? Read more about it here??https://bit.ly/3ORkOZn

from their abstract: "we report the optimization of a series of epidermal growth factor receptor (EGFR) Exon20 insertion (Ex20Ins) inhibitors using structure-based drug design (SBDD), leading to the discovery of compound 28, a potent and wild type selective molecule, which demonstrates efficacy in multiple EGFR Ex20Ins xenograft models and blood–brain barrier penetration in preclinical species. Building on our earlier discovery of an in vivo probe, SBDD was used to design a novel bicyclic core with a lower molecular weight to facilitate blood–brain barrier penetration.

We are excited to share the successful progression of our partnership with Parse Biosciences, resulting in the first-ever use of Evercode Mouse BCR for B cell analysis of transgenic mice. Read the press release and connect with us at the Antibody Engineering & Therapeutics (AET) conference in San Diego to learn why the highest-quality drug developers and technology innovators are partnering with AbTherx.?https://lnkd.in/e_gPuzt4 #abtherx #transgenicmice #innovation #partnership

?? Speaker Spotlight ?? Join Kinkini Roy, PhD and 80+ LNP experts to discuss critical strategies to develop stable, safe and site specific LNP drug products at the 3rd Lipid Nanoparticles Development Europe Summit (24-26 September, Berlin). ? Take a look at the agenda:?https://ter.li/1dmn5 ? We caught up with Kinkini recently, who told us how excited they are to?be presenting their work alongside?Sandipan Dawn, PhD?in an exclusive deep-dive workshop titled ”Exploring the Rise of LNP Alternative Drug Delivery Systems”. In this hands-on session, they will compare the challenges faced with LNPs alongside polymeric systems, pinpointing translatable learnings to take forward. ? See full details of their session:?https://ter.li/1dmn5s ? Unite with these industry leaders at the ultimate end-to-end LNP development discussion, to accelerate the clinical development of lipid nanoparticles and advance the therapeutic potential for mRNA, siRNA, CRISPR, cell therapy and lots more. ? #LipidNanoparticles #DrugDevelopment #LNP #Therapeutics #mRNA #siRNA #CRISPR #CellTherapy #Pharma #Biotech #Innovation

InMed's INM-901 is a novel, small molecule drug candidate in development for the treatment of #Alzheimer's disease. Preclinical studies of INM-901 demonstrate neuroprotective effects, reduced #neuroinflammation, an ability to promote the growth of neurites and improvement in behavior, cognitive function and memory. INM-901 may target several biological pathways associated with #AlzheimersDisease with studies indicating it targets CB1, CB2 and PPAR pathways. CEO Eric A. Adams presents InMed's INM-901 program in this video: https://ow.ly/41Ab50SWjN9 $INM

The Antibody and Engineering Therapeutics Europe conference is next week! Join Stefanie Kall, Ph.D. for a talk on how to de-risk your antibody development workflows using high-resolution thermal and colloidal stability data on your antibody constructs. Stop by booth #18 to chat more about antibody stability characterization. #AntibodyEng